ClinicalTrials.gg
RecruitingNCT06360133Updated Aug 20, 2026

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease

A Phase 3 interventional study of VVN001 Ophthalmic Solution, 5% and VVN001 Ophthalmic Solution, Vehicle in Dry Eye, sponsored by VivaVision Biotech, Inc. Recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by VivaVision Biotech, Inc · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Dry Eye Syndromes with a site in China — 28 open to participants now, 30 under way, 3 of them phase 3. Dry Eye Syndromes · China.

Planned enrollment
3rd of 83
700 · median 80
Started
2024
with 9 others
Phase 3
10 of 106
3 open now
Primary completion
2027-04
later than 22 of 29 live
Registered
73rd of 106
by date

Among the 106 studies in Dry Eye Syndromes with a site in China, this one is the 3rd largest by planned enrollment of the 83 interventional ones that give a count, is one of 10 that started in 2024, is one of 10 in phase 3, reaches primary completion later than 22 of the 29 other live ones, and was the 73rd registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

28 of the 106 studies in Dry Eye Syndromes with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Dry Eye Syndromes with a site in China, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provided written prior to any study-related procedures.
  • Are between 30 and 80 years of age.
  • Have a history of dry eye disease in both eyes.
  • Have been using artificial tears within 30 days of the screening visit
  • Have an Eye dryness score ≥50 (0-100 point VAS)
  • Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the following criteria in the study eye and the same eye at Visit 1 and Visit 2: 1) total CFS (tCFS) score ≥6; 2) any subregion CS score ≥2.5; 3) Schirmer score (without anesthesia) ≥1 and ≤7 mm/5 min.
  • Have a BCVA in the study eye of ≥4.3 (Standard for Logarithmic Visual Acuity Charts, 5-mark record).

Exclusion criteria

Exclusion Criteria:

  • Have a known or to the IP or components of IP.
  • Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the screening visit or are being treated with eye drops for glaucoma in the study eye. Or the subject has had laser or surgery for glaucoma in the study eye within 90 days of the study.
  • Woman of (WOCP) who are pregnant, lactating, or preparing for pregnant.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    VVN001

    VVN001 Ophthalmic Solution, 5%

    Drug: VVN001 Ophthalmic Solution, 5%

  • Placebo comparator
    Vehicle

    VVN001 Ophthalmic Solution, Vehicle

    Drug: VVN001 Ophthalmic Solution, Vehicle

Interventions

  • DrugVVN001 Ophthalmic Solution, 5%

    VVN001 Ophthalmic Solution, 5%

  • DrugVVN001 Ophthalmic Solution, Vehicle

    VVN001 Ophthalmic Solution, Vehicle

06

What researchers measure

Primary outcomes

  1. Corneal Fluorescein Staining

    Mean Change from baseline (Visit 2) to Day84 (Visit 6) in total corneal fluorescein staining (tCFS) using modified NEI/Industry Workshop (0-4 scale, using 0.5 unit increments).

    Time frame: Day 84

Secondary outcomes

  1. Eye Dryness

    Mean Change from baseline (Visit 2) to Day 84 (Visit 6) in the individual symptom of eye dryness (0\~100 VAS scale).

    Time frame: Day 84

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's planned 36 months is above that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2024
First posted
Apr 11, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06360133
Lead sponsor
VivaVision Biotech, Inc
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
Apr 1, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Caroline Lu
Contact
caroline.lu@vivavisionbio.com
86-18816562189
Xinghuai Sun
principal investigator · Eye & ENT Hospital of Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion